Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Successful Annual General Meeting Confirms Director Slate for 2020 VANCOUVER, Dec. 23, 2019 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "Company"), a...
Notable Milestones for the Company's Programs VANCOUVER, Nov. 26, 2019 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA: P6P2) ("RepliCel" or the "Company"), a company developing...
A paper entitled, "Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study", has been published summarizing the data from RepliCel's clinical trial of RCS-01...
YOFOTO (China) Health Now Commissioning its Manufacturing Facility in Preparation for Technology Transfer of Skin and Tendon Product Manufacturing and Applications for Clinical Trials VANCOUVER, Sept....
Management strengthens its commitment to a successful upcoming market launch of RepliCel's dermal injector and consumables product line by addition of Damien King VANCOUVER, Aug. 29, 2019 /CNW/ -...
Tendon Regeneration, Skin Rejuvenation and Dermal Injector Patents Granted in the United States, Europe, South Africa, Hong Kong, China, and Japan VANCOUVER, April 16, 2019 /CNW/ - RepliCel Life...
YOFOTO (China) Health Announces Initiation of Facility Build-Out, New Hires, and Preparation to Submit Applications to China's Regulators VANCOUVER, March 26, 2019 /CNW/ - RepliCel Life Sciences Inc. ...
Next-stage trials in Japan present market launch opportunities for RepliCel's skin and tendon products VANCOUVER, March 19, 2019 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)...
With a new strategic plan, RepliCel prioritizes focus on commercial revenue VANCOUVER, March 5, 2019 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the...
Appointment of Dr. Goessens-Rueck strengthens management team and fulfils commitment to promote female leadership in biotech VANCOUVER, Nov. 06, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:...
The National Sciences and Engineering Research Council of Canada has funded a University of Victoria project aimed at collaborating with RepliCel to optimize cell culture and manufacturing...
VANCOUVER, Oct. 17, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and...
Partnership and Investment Fuel Plans for Upcoming Advancements VANCOUVER, Oct. 15, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "Company"), a...
YOFOTO (China) Health and RepliCel Life Sciences finalize investment and commence collaboration activity in Greater China VANCOUVER and NINGBO, China, Oct, 11, 2018 /CNW/ - RepliCel Life Sciences Inc....
YOFOTO (China) Health and RepliCel Life Sciences now cleared to close investment transaction and commence collaboration activity in Greater China VANCOUVER and NINGBO, China, Sept. 24, 2018 /CNW/ -...
Skin rejuvenation and tendon regeneration products to be commercialized in Greater China in partnership with YOFOTO (China) Health Industry Co. Ltd VANCOUVER and NINGBO, Zhejiang Province, China,...
A revised binding term sheet reflects improved terms, and positions the parties for closing the transaction VANCOUVER and NINGBO, Zhejiang Province, China, May 2, 2018 /CNW/ - RepliCel Life Sciences...
With a new Asian partnership and 2017 deliverables met, RepliCel is primed and ready for expansion VANCOUVER, Jan. 25, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2)...
YOFOTO (China) Health Industry Co. Ltd to Invest in Becoming RepliCel's Strategic Partner for Greater China Terms Include an Up-front Investment of USD $6.5 Million with Direct Non-Dilutive Program...
Shareholders commit to non-brokered private placement in clear support of the Company's partnership strategy /NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE...
VANCOUVER, Sept. 22, 2017 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and...
Due diligence and confidential discussions now moving into negotiations for products in both the tendon repair and aesthetics franchises VANCOUVER, Sept. 13, 2017 /CNW/ - RepliCel Life Sciences Inc....
Delivery of RepliCel's patented prototypes kick-starts functional testing, matures licensing discussions, and confirms commercialization schedule VANCOUVER, Sept. 7, 2017 /CNW/ - RepliCel Life...
"We believe that this novel therapy has the potential to rejuvenate skin in a way we've never seen before", states key opinion leader in dermatology research DUSSELDORF, Germany, Aug. 10, 2017 /CNW/...
Data from this project expected to take RepliCel's products to next level of potential commercial viability VANCOUVER, June 13, 2017 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.